Sjogren’s Syndrome: Recent Updates
Author Contributions
Funding
Conflicts of Interest
References
- Mavragani, C.P.; Moutsopoulos, H.M. Sjögren Syndrome Review. Can. Med. Assoc. J. 2014, 186, 579–586. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kassan, S.S.; Moutsopoulos, H.M. Clinical Manifestations and Early Diagnosis of Sjögren Syndrome. Arch. Intern. Med. 2004, 164, 1275–1284. [Google Scholar] [CrossRef]
- Mavragani, C.P.; Crow, M.K. Activation of the Type I Interferon Pathway in Primary Sjogren’s Syndrome. J. Autoimmun. 2010, 35, 225–231. [Google Scholar] [CrossRef]
- Nezos, A.; Gravani, F.; Tassidou, A.; Kapsogeorgou, E.K.; Voulgarelis, M.; Koutsilieris, M.; Crow, M.K.; Mavragani, C.P. Type I and II Interferon Signatures in Sjogren’s Syndrome Pathogenesis: Contributions in Distinct Clinical Phenotypes and Sjogren’s Related Lymphomagenesis. J. Autoimmun. 2015, 63, 47–58. [Google Scholar] [CrossRef] [Green Version]
- Bodewes, I.L.A.; Versnel, M.A. Interferon Activation in Primary Sjögren’s Syndrome: Recent Insights and Future Perspective as Novel Treatment Target. Expert Rev. Clin. Immunol. 2018, 14, 817–829. [Google Scholar] [CrossRef] [PubMed]
- Papadopoulos, V.; Skarlis, C.; Evangelopoulos, M.-E.; Mavragani, C.P. Type I Interferon Detection in Autoimmune Diseases: Challenges and Clinical Applications. Expert Rev. Clin. Immunol. 2021, 17, 883–903. [Google Scholar] [CrossRef] [PubMed]
- Zintzaras, E.; Voulgarelis, M.; Moutsopoulos, H.M. The Risk of Lymphoma Development in Autoimmune Diseases: A Meta-Analysis. Arch. Intern. Med. 2005, 165, 2337–2344. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lazarus, M.N.; Robinson, D.; Mak, V.; Møller, H.; Isenberg, D.A. Incidence of Cancer in a Cohort of Patients with Primary Sjogren’s Syndrome. Rheumatology 2006, 45, 1012–1015. [Google Scholar] [CrossRef] [Green Version]
- Skarlis, C.; Argyriou, E.; Mavragani, C.P. Lymphoma in Sjögren’s Syndrome: Predictors and Therapeutic Options. Curr. Treat. Options Rheumatol. 2020, 6, 1–17. [Google Scholar] [CrossRef]
- Huijser, E.; Versnel, M.A. Making Sense of Intracellular Nucleic Acid Sensing in Type I Interferon Activation in Sjögren’s Syndrome. J. Clin. Med. 2021, 10, 532. [Google Scholar] [CrossRef]
- Sebastian, A.; Madej, M.; Sebastian, M.; Łuczak, A.; Gajdanowicz, P.; Zemelka-Wiącek, M.; Wiland, P. The Clinical and Immunological Activity Depending on the Presence of Interferon γ in Primary Sjögren’s Syndrome—A Pilot Study. J. Clin. Med. 2022, 11, 3. [Google Scholar] [CrossRef] [PubMed]
- Skarlis, C.; Marketos, N.; Nezos, A.; Papanikolaou, A.; Voulgarelis, M.; Koutsilieris, M.; Moutsopoulos, H.M.; Mavragani, C.P. +3179G/A Insulin-Like Growth Factor-1 Receptor Polymorphism: A Novel Susceptibility Contributor in Anti-Ro/SSA Positive Patients with Sjögren’s Syndrome: Potential Clinical and Pathogenetic Implications. J. Clin. Med. 2021, 10, 3960. [Google Scholar] [CrossRef] [PubMed]
- Błochowiak, K.; Celichowski, P.; Kempisty, B.; Iwanik, K.; Nowicki, M. Transcriptomic Profile of Genes Encoding Proteins Involved in Pathogenesis of Sjögren’s Syndrome Related Xerostomia-Molecular and Clinical Trial. J. Clin. Med. 2020, 9, 3299. [Google Scholar] [CrossRef] [PubMed]
- Katsiougiannis, S.; Tenta, R.; Skopouli, F.N. Endoplasmic Reticulum Stress Causes Autophagy and Apoptosis Leading to Cellular Redistribution of the Autoantigens Ro/Sjögren’s Syndrome-Related Antigen A (SSA) and La/SSB in Salivary Gland Epithelial Cells. Clin. Exp. Immunol. 2015, 181, 244–252. [Google Scholar] [CrossRef] [Green Version]
- Christodoulou, M.I.; Kapsogeorgou, E.K.; Moutsopoulos, H.M. Characteristics of the Minor Salivary Gland Infiltrates in Sjögren’s Syndrome. J. Autoimmun. 2010, 34, 400–407. [Google Scholar] [CrossRef]
- Joachims, M.L.; Leehan, K.M.; Dozmorov, M.G.; Georgescu, C.; Pan, Z.; Lawrence, C.; Marlin, M.C.; Macwana, S.; Rasmussen, A.; Radfar, L.; et al. Sjögren’s Syndrome Minor Salivary Gland CD4+ Memory T Cells Associate with Glandular Disease Features and Have a Germinal Center T Follicular Helper Transcriptional Profile. J. Clin. Med. 2020, 9, 2164. [Google Scholar] [CrossRef]
- Jonsson, R.; Brokstad, K.A.; Jonsson, M.V.; Delaleu, N.; Skarstein, K. Current Concepts on Sjögren’s Syndrome—Classification Criteria and Biomarkers. Eur. J. Oral. Sci. 2018, 126, 37–48. [Google Scholar] [CrossRef] [PubMed]
- Skarlis, C.; Palli, E.; Nezos, A.; Koutsilieris, M.; Mavragani, C.P. Study of the Incidence of Osteoporosis in Patients with Sjögren’s Syndrome (PSS) and Investigation of Activation of the RANKL /RANK and Osteoprotegerin (OPG) System. Mediterr. J. Rheumatol. 2018, 29, 224–227. [Google Scholar] [CrossRef]
- Rozis, M.; Vlamis, J.; Vasiliadis, E.; Mavragani, C.; Pneumaticos, S.; Evangelopoulos, D.S. Musculoskeletal Manifestations in Sjogren’s Syndrome: An Orthopedic Point of View. J. Clin. Med. 2021, 10, 1574. [Google Scholar] [CrossRef]
- Koulouri, V.; Koutsilieris, M.; Mavragani, C.P. B Cells and Atherosclerosis in Systemic Lupus Erythematosus. Expert Rev. Clin. Immunol. 2019, 15, 417–429. [Google Scholar] [CrossRef]
- Giannelou, M.; Skarlis, C.; Stamouli, A.; Antypa, E.; Moutsopoulos, H.M.; Mavragani, C.P. Atherosclerosis in SLE: A Potential Role for Serum Parathormone Levels. Lupus Sci. Med. 2020, 7, e000393. [Google Scholar] [CrossRef]
- Gravani, F.; Papadaki, I.; Antypa, E.; Nezos, A.; Masselou, K.; Ioakeimidis, D.; Koutsilieris, M.; Moutsopoulos, H.M.; Mavragani, C.P. Subclinical Atherosclerosis and Impaired Bone Health in Patients with Primary Sjogren’s Syndrome: Prevalence, Clinical and Laboratory Associations. Arthritis Res. Ther. 2015, 17, 99. [Google Scholar] [CrossRef] [Green Version]
- Bartoloni, E.; Alunno, A.; Valentini, V.; Valentini, E.; La Paglia, G.M.C.; Leone, M.C.; Cafaro, G.; Marcucci, E.; Bonifacio, A.F.; Luccioli, F.; et al. The Prevalence and Relevance of Traditional Cardiovascular Risk Factors in Primary Sjögren’s Syndrome. Clin. Exp. Rheumatol. 2018, 36 (Suppl. S112), 113–120. [Google Scholar]
- Yang, D.-H.; Wang, Y.-H.; Pan, L.-F.; Wei, J.C.-C. Cardiovascular Protection of Hydroxychloroquine in Patients with Sjögren’s Syndrome. J. Clin. Med. 2020, 9, 3469. [Google Scholar] [CrossRef]
- Yusuf, I.H.; Sharma, S.; Luqmani, R.; Downes, S.M. Hydroxychloroquine Retinopathy. Eye 2017, 31, 828–845. [Google Scholar] [CrossRef] [PubMed]
- Stergiou, I.E.; Poulaki, A.; Voulgarelis, M. Pathogenetic Mechanisms Implicated in Sjögren’s Syndrome Lymphomagenesis: A Review of the Literature. J. Clin. Med. 2020, 9, 3794. [Google Scholar] [CrossRef] [PubMed]
- Chatzis, L.; Pezoulas, V.C.; Ferro, F.; Gandolfo, S.; Donati, V.; Binutti, M.; Callegher, S.Z.; Venetsanopoulou, A.; Zampeli, E.; Mavrommati, M.; et al. Sjögren’s Syndrome: The Clinical Spectrum of Male Patients. J. Clin. Med. 2020, 9, 2620. [Google Scholar] [CrossRef]
- Theander, E.; Mandl, T. Primary Sjögren’s Syndrome: Diagnostic and Prognostic Value of Salivary Gland Ultrasonography Using a Simplified Scoring System. Arthritis Care Res. 2014, 66, 1102–1107. [Google Scholar] [CrossRef]
- Van Mello, N.M. B Cell MALT Lymphoma Diagnosed by Labial Minor Salivary Gland Biopsy in Patients Screened for Sjogren’s Syndrome. Ann. Rheum. Dis. 2004, 64, 471–473. [Google Scholar] [CrossRef] [PubMed]
- Manfrè, V.; Giovannini, I.; Zandonella Callegher, S.; Lorenzon, M.; Pegolo, E.; Tel, A.; Gandolfo, S.; Quartuccio, L.; De Vita, S.; Zabotti, A. Ultrasound and Bioptic Investigation of Patients with Primary Sjögren’s Syndrome. J. Clin. Med. 2021, 10, 1171. [Google Scholar] [CrossRef]
- Nezos, A.; Evangelopoulos, M.-E.; Mavragani, C.P. Genetic Contributors and Soluble Mediators in Prediction of Autoimmune Comorbidity. J. Autoimmun. 2019, 104, 102317. [Google Scholar] [CrossRef] [PubMed]
- Argyriou, E.; Nezos, A.; Roussos, P.; Venetsanopoulou, A.; Voulgarelis, M.; Boki, K.; Tzioufas, A.G.; Moutsopoulos, H.M.; Mavragani, C.P. Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3): A Novel Marker for Lymphoma Development among Patients with Young Onset Sjogren’s Syndrome. J. Clin. Med. 2021, 10, 644. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Skarlis, C.; Raftopoulou, S.; Mavragani, C.P. Sjogren’s Syndrome: Recent Updates. J. Clin. Med. 2022, 11, 399. https://doi.org/10.3390/jcm11020399
Skarlis C, Raftopoulou S, Mavragani CP. Sjogren’s Syndrome: Recent Updates. Journal of Clinical Medicine. 2022; 11(2):399. https://doi.org/10.3390/jcm11020399
Chicago/Turabian StyleSkarlis, Charalampos, Sylvia Raftopoulou, and Clio P. Mavragani. 2022. "Sjogren’s Syndrome: Recent Updates" Journal of Clinical Medicine 11, no. 2: 399. https://doi.org/10.3390/jcm11020399
APA StyleSkarlis, C., Raftopoulou, S., & Mavragani, C. P. (2022). Sjogren’s Syndrome: Recent Updates. Journal of Clinical Medicine, 11(2), 399. https://doi.org/10.3390/jcm11020399